PHAT NASDAQ
Florham Park, NJ 07932
US
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Breedlove Robert Cha | F-InKind | 1,555 | $11.04 | 2026-07-14 |
| Parikh Asit | G-Gift | 28,000 | — | 2026-05-22 |
| Parikh Asit | G-Gift | 28,000 | — | 2026-05-22 |
| Parikh Asit | M-Exempt | 17,500 | $4.95 | 2026-05-20 |
| Parikh Asit | D-Return | 17,500 | $4.95 | 2026-05-20 |